1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies

Mario Gabelli Comments on Amgen Inc.

January 06, 2014 | About:

Amgen Inc. (0.2%) (AMGN - $111.94 - NASDAQ)(AMGN) is one of the largest biotechnology companies in the world, with medicines for cancer, kidney dialysis, osteoporosis, and other conditions. Given its large size and mature product portfolio, revenue growth has slowed, but the company has been able to cut costs and repurchase shares to sustain double digit earnings per share growth. Earlier this year, Amgen offered to acquire Onyx Pharmaceuticals Inc. (less than 0.1%) to bolster its oncology portfolio, with Nexavar for liver cancer and Kyprolis for blood cancers. On Aug 25, after a brief auction, Amgen agreed to pay $125 per share, or $10.4 billion, for Onyx. While initially dilutive to earnings, this acquisition provides significant visibility into Amgen's future, with two blockbuster drugs that could eventually generate over $5 billion in annual sales. 

 

From Mario Gabelli (Trades, Portfolio)'s third quarter 2013 commentary.


Rating: 0.0/5 (0 votes)

Comments

Please leave your comment:


GuruFocus has detected 3 Warning Signs with Amgen Inc $AMGN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.

User Generated Screeners


utche96Piot>7,P/FCF,Rev
rael222210
Bogdan BednarskiCSROE2008,ROIC 15-75,ROIC 5Y >
bdietzBook Growth Rate
pbarker46Median PS
Bogdan Bednarski4Star, ROIC Up Tr, ROIC > WACC
yasarkhana/c_2B
yasarkhantest_g
yasarkhantest_j
psinghppm(EV/MC)+(P-50)_no_price
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK